Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Comment by lscfaon Dec 25, 2022 9:25pm
194 Views
Post# 35191765

RE:RE:RE:RE:Buyout

RE:RE:RE:RE:Buyout
lscfa wrote:

UglyKidStock wrote: Shareholder Robbery under the distraction of Xmas.    Stealing it for debt - cash with no stock option over hang and all of the good news on approvals coming in first half 2023.    Without the options 'warrants owed to Red Oak the Enterprise value is quite low.  These things were rapidly expiring already.   What is Red Oaks angle ?  
I agree it's highway robbery and a sellout by mgmt.  NR does not mention co. had $31 million CAD in cash at Sept 30, making net debt only $75 million CAD. This means the buyout offer only values next year's ebitda at 4.165x using Bllom Burton's forecast of ebitda. If the multiple is raised to 5x the offer would need to be $2.94/sh. I'm voting no to this stink bid.


https://www.bloomburton.com/research/MRV20221116.pdf

 





 

 

$ 000 Cdn

Buy out offer

Increased multiple

2023 ebitda 

21.7

21.7

Multiple

4.165

5

eV

90.4

108.5

Net Debt

75

75

Equity value

15.4

33.5

Shs o/s

11.4

11.4

Sh value

$1.35

$2.94

 

 



more pricing options added to table...


 

$ 000 Cdn

Buy out offer

Increased multiple

Increased multiple

Increased multiple

2023 ebitda 

21.7

21.7

21.7

21.7

Multiple

4.165

4.5

4.75

5

eV

90.4

97.7

103.1

108.5

Net Debt

75

75

75

75

Equity value

15.4

22.7

28.1

33.5

Shs o/s

11.4

11.4

11.4

11.4

Sh value

$1.35

$1.99

$2.46

$2.94

 


<< Previous
Bullboard Posts
Next >>